Holen Sie sich die Stockscreener-App
5.38
15.67%
-1.00
Handel nachbörslich:
5.71
0.33
+6.13%
Schlusskurs vom Vortag:
$6.38
Offen:
$6.44
24-Stunden-Volumen:
129.36K
Relative Volume:
4.96
Marktkapitalisierung:
$21.78M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.85M
KGV:
-0.9456
EPS:
-5.6896
Netto-Cashflow:
$-13.20M
1W Leistung:
-26.40%
1M Leistung:
-61.57%
6M Leistung:
-87.57%
1J Leistung:
-90.31%
1-Tages-Spanne:
$5.204
$7.4786
1-Wochen-Bereich:
$5.204
$8.1299
52-Wochen-Spanne:
$5.204
$75.50
Tevogen Bio Holdings Inc Stock (TVGN) Company Profile
Firmenname
Tevogen Bio Holdings Inc
Sektor
Branche
Telefon
646-807-8832
Adresse
15 INDEPENDENCE BOULEVARD, SUITE #210, WARREN
Compare TVGN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVGN
Tevogen Bio Holdings Inc
|
5.38 | 25.83M | 0 | -30.85M | -13.20M | -5.6896 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tevogen Bio Holdings Inc Stock (TVGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-04 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2025-03-04 | Eingeleitet | D. Boral Capital | Buy |
Tevogen Bio Holdings Inc Aktie (TVGN) Neueste Nachrichten
Tevogen reports performance advancements for Tevogen.AI platform - TipRanks
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization - The Globe and Mail
Tevogen Bio Advances AI Drug Development Platform with Improved Predictive Accuracy for Target Identification - Quiver Quantitative
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics ... - Caledonian Record
Inside the AI model Tevogen is training to cut trial-and-error in drug R&D - Stock Titan
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform - Finviz
Wall Street Recap: Is Tevogen Bio Holdings Inc Equity Warrant undervalued by DCF analysisEarnings Overview Report & Real-Time Market Trend Scan - baoquankhu1.vn
Tevogen Bio Holdings Inc. is considering the acquisition of Sciometrix and Clinicus platforms to enhance its monitoring capabilities for Long Covid. - Bitget
Tevogen Bio Accelerates Development of TVGN 489 for Long COVID with New Leadership and Strategic Initiatives - Quiver Quantitative
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform - GlobeNewswire Inc.
Tevogen appoints interim leaders across core business verticals - TipRanks
Tevogen Bio Holdings Inc. Appoints Interim Leaders to Drive Diversified Growth Strategy - Quiver Quantitative
Inside Tevogen's $50M expansion push and the team picked to run it - Stock Titan
Total debt of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Total operating expenses of Tevogen Bio Holdings Inc. – FWB:G280 - TradingView
Operating income of Tevogen Bio Holdings Inc. – TRADEGATE:G280 - TradingView
Tevogen Bio Holdings Inc. Income Statement – FWB:G280 - TradingView
Market Review: Is Tevogen Bio Holdings Inc Equity Warrant undervalued by DCF analysis - baoquankhu1.vn
Portfolio Shifts: Why is Tevogen Bio Holdings Inc Equity Warrant stock going upWeekly Trade Review & Expert Verified Movement Alerts - baoquankhu1.vn
Letter to Shareholders from CEO Dr. Ryan Saadi - The Globe and Mail
Tevogen CEO says ‘actively evaluating potential acquisitions’ - TipRanks
Tevogen Bio explores acquisitions that may add $50M+ in yearly revenue - Stock Titan
Tevogen Bio Explores Buyout To Boost Generics Platform - Benzinga
Tevogen Bio (NASDAQ:TVGN) Sets New 12-Month LowHere's What Happened - MarketBeat
Marvell Technology, Day One Biopharmaceuticals, Samsara And Other Big Stocks Moving Higher On Friday - Benzinga
Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical - Sahm
Tevogen Bio Signs Letter of Intent to Evaluate Potential Apozeal Pharmaceutical Acquisition - marketscreener.com
U.S. federal banking regulators clarify capital treatment rules for tokenized securities - Bitget
Tevogen Bio Holdings (Tevogen) has recently taken a key step in its generic drug business strategy, signing a letter of intent to officially begin evaluating the potential acquisition of Apozeal Pharmaceuticals. - Bitget
Tevogen Bio Holdings Inc is currently actively evaluating other transaction opportunities and has strategically focused its priorities on businesses related to the life sciences sector. - Bitget
Tevogen Bio Holdings Inc. Signs Letter of Intent to Explore Acquisition of Apozeal Pharmaceutical Inc. for Generics Expansion - Quiver Quantitative
Tevogen Announces Reverse Stock Split - Bitget
TVGN Downgrade: Analyst Shifts Rating from Buy to Hold | TVGN St - GuruFocus
Tevogen Shares Plunge 22% After Reverse Stock Split Announcement - Nasdaq
Tevogen Bio Announces 1-for-50 Reverse Stock Split - TipRanks
1-for-50 Reverse Split Effective Mar 6, 2026 — Tevogen (NASDAQ: TVGN) - Stock Titan
Tevogen Bio (Nasdaq: TVGN) sets 1-for-50 reverse stock split to meet Nasdaq bid rule - Stock Titan
Tevogen announces reverse stock split - marketscreener.com
Tevogen to swap every 50 shares for 1 in bid to meet Nasdaq rules - Stock Titan
TVGN: Analyst Lowers Price Target by 60% While Maintaining Buy R - GuruFocus
D. Boral Capital lowers Tevogen Bio stock price target to $2 on dilution risk By Investing.com - Investing.com South Africa
D. Boral Capital lowers Tevogen Bio stock price target to $2 on dilution risk - Investing.com
Tevogen Bio Signs Letter of Intent to Explore Contract Research Organization Acquisition - marketscreener.com
Tevogen Bio Holdings Inc. Signs Non-Binding Letter of Intent to Explore Potential Transaction with Global Contract Research Organization - Quiver Quantitative
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization - Taiwan News
Tevogen weighs CRO acquisition to add service revenue, optimize trials - Stock Titan
UPDATETevogen Signs Letter of Intent to Evaluate - GlobeNewswire
Tevogen signs loi to evaluate potential acquisition of Sciometrix - marketscreener.com
Tevogen (NASDAQ: TVGN) approves reverse split and 100M plan increase - Stock Titan
Tevogen Bio Holdings Inc. Signs Letter of Intent to Explore Acquisition of Sciometrix Inc. for Enhanced Healthcare Solutions | TVGN Stock News - Quiver Quantitative
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus - Taiwan News
Finanzdaten der Tevogen Bio Holdings Inc-Aktie (TVGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):